secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2021-08-18T23:59:59+00:00
Accession:  0001437749-21-020423
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KemPharm appoints Tamara A. Seymour to board and audit committee chair
----------------------------------------------------------------------

- Appointment effective August 18, 2021; Seymour becomes Class I director, term expiring at 2022 annual meeting.
- Seymour brings over 30 years life sciences experience, including CFO roles at several public and private biotech firms.
- Initial grant of 22,500 stock options vesting in three equal annual installments under 2014 equity plan.
- Annual retainers: $35,000 for board service and $22,500 for audit committee chair.
- CEO notes appointment comes at 'important phase' as KemPharm seeks organic and external growth opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774921020423/0001437749-21-020423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774921020423/kmph20210817_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-020423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer